Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics
Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics ZURICH, Oct 13 (Reuters) - Swiss drugmaker Roche ROPC.S entered a licensing agreement worth up to $1.16 billion with Rona Therapeutics for its investigational obesity drug candidate, the Chinese biotech firm said on Tuesday.
Roche has been racing to break into the obesity drug market dominated by Eli Lilly LLY.N and Novo Nordisk NOVOb.CO.
With the deal, Rona Therapeutics is set to receive an upfront payment of $100 million and is eligible to receive up to $1.06 billion in potential milestone payments, as well as tiered royalties on global net sales.
The investigational RNAi candidate targets activin receptor-like kinase 7 (ALK7), a target for obesity and metabolic diseases.
In September, Roche reported positive mid-stage data for its obesity and diabetes candidate enicepatide, which helped patients lose weight and lower blood sugar levels.
(Reporting by Marleen Kaesebier
Editing by Linda Pasquini)
((marleen.kaesebier@thomsonreuters.com))
Recent news on Novo Nordisk A/S
See all newsFocus: Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Factbox: Anthropic's public benefit fund and how it compares with other big philanthropic efforts
Novo's CagriSema helped women lose 25% of weight on average, analysis shows
As weight-loss drug users turn to dietary supplements, doctors, regulators raise flags
Factbox: Major drugmakers turn to China for licensing deals